Summary
GlobalData's clinical trial report, “Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016" provides an overview of Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Chylomicronemia (Type I Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies Mentioned
Ionis Pharmaceuticals, Inc.
Novartis AG
Medpace Holdings, Inc.
Aegerion Pharmaceuticals, Inc.
UniQure N.V.
Richmond Pharmacology Limited
Kadmon Corporation, LLC
ICON Plc
Catabasis Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Top Countries Contributing to Clinical Trials in Middle East and Africa 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 16
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials 25
Prominent Drugs 27
Latest Clinical Trials News on Familial Chylomicronemia (Type I Hyperlipoproteinemia) 28
Jun 27, 2016: Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes 28
Clinical Trial Profile Snapshots 29
Appendix 38
Abbreviations 38
Definitions 38
Research Methodology 39
Secondary Research 39
About GlobalData 40
Contact Us 40
Disclaimer 40
Source 41
List of Tables
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 9
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2016* 10
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 11
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 12
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 13
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2016* 18
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 19
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 23
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27
List of Figures
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 9
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 11
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 13
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 16
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 18
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 19
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 23
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 25
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27
GlobalData Methodology 39
